SCHEMBL3399579

SCHEMBL3399579

Cc1nc(-c2ccc(F)c(Cl)c2)sc1C(=O)N1CCN(C(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.47
THRA P10827 2/20 0.44
THRB P10828 2/20 0.44
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 2/20 0.42
MET P08581 1/20 0.42
HTR2C P28335 3/20 0.41
CHRNA7 P36544 1/20 0.41
GAA P10253 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
CDK6 Q00534 1/20 0.39
PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405774 0.92 CNR1 (0.47) CNR1THRATHRBRAB9ASMN1; SMN2
SCHEMBL3405229 0.91 CNR1 (0.49) CNR1THRATHRBRAB9ASMN1; SMN2
SCHEMBL3398373 0.91 CNR1 (0.49) CNR1THRATHRBRAB9ASMN1; SMN2
SCHEMBL3406022 0.90 CNR1 (0.48) CNR1THRATHRBRAB9ASMN1; SMN2
SCHEMBL3398495 0.88 CNR1 (0.48) CNR1THRATHRBRAB9AKDM4E
SCHEMBL3399712 0.85 CNR1 (0.44) CNR1THRATHRBRAB9ASMN1; SMN2
SCHEMBL3405550 0.85 CNR1 (0.55) CNR1THRATHRBRAB9ASMN1; SMN2
SCHEMBL3403580 0.85 CNR1 (0.49) CNR1THRATHRBRAB9ASMN1; SMN2
SCHEMBL3399685 0.85 CNR1 (0.55) CNR1THRATHRBRAB9ASMN1; SMN2
SCHEMBL3402351 0.84 CNR1 (0.45) CNR1THRATHRBSMN1; SMN2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 CNR1 35/4885THRA 38/4885THRB 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.